{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T10:31:26Z","timestamp":1773138686613,"version":"3.50.1"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020406","name":"Dr. Falk Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020406","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bpg.2025.102081","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T07:46:21Z","timestamp":1765266381000},"page":"102081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Persistent symptoms and enteropathy in coeliac disease: clinical considerations and therapeutic opportunities"],"prefix":"10.1016","volume":"79","author":[{"given":"Maxim","family":"D'heedene","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason A.","family":"Tye-Din","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3195-4996","authenticated-orcid":false,"given":"Lucas","family":"Wauters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10344","key":"10.1016\/j.bpg.2025.102081_bib1","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/S0140-6736(22)00794-2","article-title":"Coeliac disease","volume":"399","author":"Catassi","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bpg.2025.102081_bib2","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cgh.2017.06.037","article-title":"Global prevalence of celiac disease: systematic review and meta-analysis","volume":"16","author":"Singh","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2025.102081_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.14309\/ajg.0000000000000523","article-title":"Incidence of celiac disease is increasing over time: a systematic review and meta-analysis","volume":"115","author":"King","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2025.102081_bib4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.14309\/ajg.0000000000002075","article-title":"American college of gastroenterology guidelines update: diagnosis and management of celiac disease","volume":"118","author":"Rubio-Tapia","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2025.102081_bib5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/ajg.2013.47","article-title":"A randomized controlled trial of an online intervention to improve gluten-free diet adherence in celiac disease","volume":"108","author":"Sainsbury","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.bpg.2025.102081_bib6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2036.2009.04053.x","article-title":"Systematic review: adherence to a gluten-free diet in adult patients with coeliac disease","volume":"30","author":"Hall","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.bpg.2025.102081_bib7","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/apt.12164","article-title":"Mucosal healing and mortality in coeliac disease","volume":"37","author":"Lebwohl","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.bpg.2025.102081_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/jgh3.13107","article-title":"Evolution in coeliac disease diagnosis and management","volume":"8","author":"Tye-Din","year":"2024","journal-title":"JGH Open"},{"issue":"5","key":"10.1016\/j.bpg.2025.102081_bib9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/apt.12621","article-title":"Predictors of persistent villous atrophy in coeliac disease: a population-based study","volume":"39","author":"Lebwohl","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bpg.2025.102081_bib10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cgh.2006.12.006","article-title":"Etiologies and predictors of diagnosis in nonresponsive celiac disease","volume":"5","author":"Leffler","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.bpg.2025.102081_bib11","first-page":"S49","article-title":"Review article: follow-up of coeliac disease","volume":"56","author":"Tye-Din","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.bpg.2025.102081_bib12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/MPG.0000000000001634","article-title":"Celiac disease symptom resolution: effectiveness of the gluten-free diet","volume":"66","author":"Sansotta","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"7","key":"10.1016\/j.bpg.2025.102081_bib13","first-page":"356","article-title":"Assessing mucosal recovery in celiac disease - time to diagnosis and histological severity as determining factors","volume":"116","author":"Rodr\u00edguez-Mart\u00edn","year":"2024","journal-title":"Rev Esp Enferm Dig"},{"issue":"6","key":"10.1016\/j.bpg.2025.102081_bib14","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/ajg.2010.10","article-title":"Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet","volume":"105","author":"Rubio-Tapia","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2025.102081_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3389\/fnut.2019.00153","article-title":"Toward new paradigms in the follow up of adult patients with celiac disease on a gluten-free diet","volume":"6","author":"Pinto-Sanchez","year":"2019","journal-title":"Front Nutr"},{"issue":"3","key":"10.1016\/j.bpg.2025.102081_bib16","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41575-023-00872-2","article-title":"Guidelines for best practices in monitoring established coeliac disease in adult patients","volume":"21","author":"Elli","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2025.102081_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/jgh.16808","article-title":"Prevalence and etiologies of non-responsive celiac disease: a systematic review and meta-analysis","volume":"40","author":"Aggarwal","year":"2025","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.bpg.2025.102081_bib18","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/j.1572-0241.2002.05917.x","article-title":"Etiology of nonresponsive celiac disease: results of a systematic approach","volume":"97","author":"Abdulkarim","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"13","key":"10.1016\/j.bpg.2025.102081_bib19","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3748\/wjg.v27.i13.1311","article-title":"Non-responsive celiac disease in children on a gluten free diet","volume":"27","author":"Veeraraghavan","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.bpg.2025.102081_bib20","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.cgh.2020.03.038","article-title":"Real-World gluten exposure in patients with celiac disease on gluten-free diets, determined from gliadin immunogenic peptides in urine and fecal samples","volume":"19","author":"Stefanolo","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2025.102081_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/nu12010216","article-title":"Non-responsive coeliac disease: a comprehensive review from the NHS England national centre for refractory coeliac disease","volume":"12","author":"Penny","year":"2020","journal-title":"Nutrients"},{"issue":"7","key":"10.1016\/j.bpg.2025.102081_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/nu8070429","article-title":"Gastrointestinal symptoms in celiac disease patients on a long-term gluten-free diet","volume":"8","author":"Laurikka","year":"2016","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.bpg.2025.102081_bib23","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.cgh.2012.11.033","article-title":"Prevalence of irritable bowel syndrome-type symptoms in patients with celiac disease: a meta-analysis","volume":"11","author":"Sainsbury","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.bpg.2025.102081_bib24","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1007\/s10620-022-07727-x","article-title":"High prevalence of functional gastrointestinal disorders in celiac patients with persistent symptoms on a gluten-free diet: a 20-Year Follow-Up study","volume":"68","author":"Schiepatti","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.bpg.2025.102081_bib25","first-page":"51","article-title":"Clinical presentation and spectrum of gluten symptomatology in celiac disease","volume":"167","author":"Adams","year":"2024","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.bpg.2025.102081_bib26","doi-asserted-by":"crossref","first-page":"791","DOI":"10.14309\/ajg.0000000000000202","article-title":"Detection of gluten in gluten-free labeled restaurant food: analysis of crowd-sourced data","volume":"114","author":"Lerner","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2025.102081_bib27","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1111\/jhn.13206","article-title":"A dietitian-led coeliac service helps to identify and reduce involuntary gluten ingestion with subsequent reduction in the frequency of repeat endoscopies","volume":"36","author":"Costas-Batlle","year":"2023","journal-title":"J Hum Nutr Diet"},{"issue":"7","key":"10.1016\/j.bpg.2025.102081_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/nu16071094","article-title":"Efficacy of a Low-FODMAP diet for coeliac patients with persistent IBS-Like symptoms despite a gluten-free diet: a systematic review","volume":"16","author":"Lusetti","year":"2024","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.bpg.2025.102081_bib29","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cgh.2021.07.026","article-title":"Functional gastrointestinal disorders and associated health impairment in individuals with celiac disease","volume":"20","author":"Parker","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.bpg.2025.102081_bib30","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1007\/s10620-017-4666-z","article-title":"Symptoms of functional intestinal disorders are common in patients with celiac disease following transition to a gluten-free diet","volume":"62","author":"Silvester","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"10","key":"10.1016\/j.bpg.2025.102081_bib31","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.cgh.2022.01.011","article-title":"A low FODMAP diet reduces symptoms in treated celiac patients with ongoing Symptoms\u2013A randomized controlled trial","volume":"20","author":"van Megen","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2025.102081_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/nu14030584","article-title":"Lactose malabsorption and presumed related disorders: a review of current evidence","volume":"14","author":"Usai-Satta","year":"2022","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.bpg.2025.102081_bib33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/nu14010002","article-title":"Nutrition in patients with lactose malabsorption, celiac disease, and related disorders","volume":"14","author":"Alkalay","year":"2021","journal-title":"Nutrients"},{"issue":"11","key":"10.1016\/j.bpg.2025.102081_bib34","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.cgh.2009.07.011","article-title":"An association between microscopic colitis and celiac disease","volume":"7","author":"Green","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2025.102081_bib35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S2468-1253(19)30048-2","article-title":"Microscopic colitis: pathophysiology and clinical management","volume":"4","author":"Miehlke","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.bpg.2025.102081_bib36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/17474124.2020.1757428","article-title":"Small intestinal bacterial overgrowth and celiac disease\u2013coincidence or causation?","volume":"14","author":"Charlesworth","year":"2020","journal-title":"Expet Rev Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.bpg.2025.102081_bib37","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000078","article-title":"Small intestinal bacterial overgrowth: clinical features and therapeutic management","volume":"10","author":"Rao","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"issue":"10","key":"10.1016\/j.bpg.2025.102081_bib38","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1111\/jgh.15920","article-title":"Links between celiac disease and small intestinal bacterial overgrowth: a systematic review and meta-analysis","volume":"37","author":"Shah","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.bpg.2025.102081_bib39","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1007\/s10620-023-07965-7","article-title":"Exocrine pancreatic insufficiency is common in celiac disease: a systematic review and meta-analysis","volume":"68","author":"Jiang","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.bpg.2025.102081_bib40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2036.2006.03206.x","article-title":"Is exocrine pancreatic insufficiency in adult coeliac disease a cause of persisting symptoms?","volume":"25","author":"Leeds","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.bpg.2025.102081_bib41","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1007\/s10620-010-1261-y","article-title":"Pancreatic insufficiency in adult celiac disease: do patients require long-term enzyme supplementation?","volume":"55","author":"Evans","year":"2010","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.bpg.2025.102081_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/nu13020600","article-title":"Relationship between persistent gastrointestinal symptoms and duodenal histological findings after adequate gluten-free diet: a gray area of celiac disease management in adult patients","volume":"13","author":"Galli","year":"2021","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.bpg.2025.102081_bib43","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1177\/2050640619844125","article-title":"European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders","volume":"7","author":"Al-Toma","year":"2019","journal-title":"United European Gastroenterol J"},{"issue":"8","key":"10.1016\/j.bpg.2025.102081_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/nu16081198","article-title":"Risk of gluten cross-contamination due to food handling practices: a mini-review","volume":"16","author":"Damasceno","year":"2024","journal-title":"Nutrients"},{"issue":"7","key":"10.1016\/j.bpg.2025.102081_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/nu13072244","article-title":"Food safety and cross-contamination of gluten-free products: a narrative review","volume":"13","author":"Wieser","year":"2021","journal-title":"Nutrients"},{"issue":"10","key":"10.1016\/j.bpg.2025.102081_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/foods11101380","article-title":"Biomarkers to monitor adherence to gluten-free diet by celiac disease patients: gluten immunogenic peptides and urinary miRNAs","volume":"11","author":"Paolini","year":"2022","journal-title":"Foods"},{"issue":"10","key":"10.1016\/j.bpg.2025.102081_bib47","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/ajg.2016.439","article-title":"Fecal gluten peptides reveal limitations of serological tests and food questionnaires for monitoring gluten-free diet in celiac disease patients","volume":"111","author":"Comino","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.bpg.2025.102081_bib48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/flgastro-2019-101191","article-title":"How to manage adult coeliac disease: perspective from the NHS England Rare Diseases Collaborative Network for Non-Responsive and Refractory Coeliac Disease","volume":"11","author":"Baggus","year":"2020","journal-title":"Frontline Gastroenterol"},{"issue":"11","key":"10.1016\/j.bpg.2025.102081_bib49","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/j.1365-2036.2008.03669.x","article-title":"Systematic review: tolerable amount of gluten for people with coeliac disease","volume":"27","author":"Akobeng","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2025.102081_bib50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-230X-13-40","article-title":"Trace gluten contamination may play a role in mucosal and clinical recovery in a subgroup of diet-adherent non-responsive celiac disease patients","volume":"13","author":"Hollon","year":"2013","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2025.102081_bib51","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000369519","article-title":"Refractory celiac disease: epidemiology and clinical manifestations","volume":"33","author":"Malamut","year":"2015","journal-title":"Dig Dis"},{"issue":"19","key":"10.1016\/j.bpg.2025.102081_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910383","article-title":"Refractory celiac disease: what the gastroenterologist should know","volume":"25","author":"Verdelho Machado","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.bpg.2025.102081_bib53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.gtc.2018.09.010","article-title":"Refractory celiac disease","volume":"48","author":"Malamut","year":"2019","journal-title":"Gastroenterol Clin N Am"},{"issue":"11","key":"10.1016\/j.bpg.2025.102081_bib54","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/j.cgh.2024.05.022","article-title":"Enduring clinical remission in refractory celiac disease type II with tofacitinib: an open-label clinical Study","volume":"22","author":"Dieckman","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.bpg.2025.102081_bib55","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/L20-0497","article-title":"Celiac disease remission with tofacitinib: a case report","volume":"173","author":"Wauters","year":"2020","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.bpg.2025.102081_bib56","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41575-020-00378-1","article-title":"Current and emerging therapies for coeliac disease","volume":"18","author":"Kivel\u00e4","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2025.102081_bib57","doi-asserted-by":"crossref","first-page":"319","DOI":"10.14309\/ajg.0000000000001565","article-title":"Plasma IL-2 and symptoms response after acute gluten exposure in subjects with celiac disease or nonceliac gluten sensitivity","volume":"117","author":"Cartee","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.bpg.2025.102081_bib58","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/apt.15477","article-title":"Elevated serum interleukin-2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease","volume":"50","author":"Tye-Din","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.bpg.2025.102081_bib59","doi-asserted-by":"crossref","first-page":"eaaw7756","DOI":"10.1126\/sciadv.aaw7756","article-title":"Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease","volume":"5","author":"Goel","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.bpg.2025.102081_bib60","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2025.05.022","article-title":"Blood-based T-Cell diagnosis of celiac disease","author":"Moscatelli","year":"2025","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bpg.2025.102081_bib62","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2023.08.051","article-title":"Standardizing randomized controlled trials in celiac disease: an international multidisciplinary appropriateness study","volume":"166","author":"Lebwohl","year":"2024","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.bpg.2025.102081_bib63","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.clnu.2024.04.014","article-title":"Celiac disease: hope for new treatments beyond a gluten-free diet","volume":"43","author":"D\u2019heedene","year":"2024","journal-title":"Clin Nutr"},{"issue":"6","key":"10.1016\/j.bpg.2025.102081_bib64","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1053\/j.gastro.2022.07.071","article-title":"Latiglutenase protects the mucosa and attenuates symptom severity in patients with celiac disease exposed to a gluten challenge","volume":"163","author":"Murray","year":"2022","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bpg.2025.102081_bib65","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.gastro.2021.03.019","article-title":"Gluten degradation, pharmacokinetics, safety, and tolerability of TAK-062, an engineered enzyme to treat celiac disease","volume":"161","author":"Pultz","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.bpg.2025.102081_bib66","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s10620-016-4426-5","article-title":"AGY, a novel egg yolk-derived anti-gliadin antibody, is safe for patients with celiac disease","volume":"62","author":"Sample","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.bpg.2025.102081_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110259","article-title":"A bispecific antibody targeting HLA-DQ2.5-gluten peptides potently blocks gluten-specific T cells induced by gluten ingestion in patients with celiac disease","volume":"264","author":"Hardy","year":"2024","journal-title":"Clin Immunol"},{"issue":"8","key":"10.1016\/j.bpg.2025.102081_bib68","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S2468-1253(23)00107-3","article-title":"Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial","volume":"8","author":"Murray","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2025.102081_bib69","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.gastro.2021.03.014","article-title":"TAK-101 nanoparticles induce gluten-specific tolerance in celiac disease: a randomized, double-blind, placebo-controlled study","volume":"161","author":"Kelly","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.bpg.2025.102081_bib70","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S2468-1253(22)00428-9","article-title":"Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study","volume":"8","author":"Tye-Din","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2025.102081_bib71","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2032441","article-title":"A randomized trial of a transglutaminase 2 inhibitor for celiac disease","volume":"385","author":"Schuppan","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.bpg.2025.102081_bib72","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S2468-1253(19)30264-X","article-title":"Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study","volume":"4","author":"L\u00e4hdeaho","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.bpg.2025.102081_bib73","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2468-1253(19)30265-1","article-title":"Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study","volume":"4","author":"Cellier","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.bpg.2025.102081_bib75","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1053\/j.gastro.2015.02.008","article-title":"Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial","volume":"148","author":"Leffler","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bpg.2025.102081_bib76","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S2468-1253(24)00248-6","article-title":"Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial","volume":"10","author":"Daveson","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2025.102081_bib78","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.gastro.2024.02.050","article-title":"How future pharmacologic therapies for celiac disease will complement the gluten-free diet","volume":"167","author":"Discepolo","year":"2024","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.bpg.2025.102081_bib79","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s10620-020-06454-5","article-title":"Enteric-release budesonide may be useful in the management of non-responsive celiac disease","volume":"66","author":"Therrien","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.bpg.2025.102081_bib80","first-page":"39","article-title":"Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis","volume":"7","author":"Iborra","year":"2014","journal-title":"Clin Exp Gastroenterol"},{"issue":"6","key":"10.1016\/j.bpg.2025.102081_bib81","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ajg.2017.71","article-title":"Open-capsule budesonide for refractory celiac disease","volume":"112","author":"Mukewar","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.bpg.2025.102081_bib82","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1007\/s10620-024-08436-3","article-title":"Budesonide induces favourable histologic and symptomatic recovery in patients with non-responsive and refractory coeliac disease when given in an open capsule format","volume":"69","author":"Saitta","year":"2024","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.bpg.2025.102081_bib83","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1053\/j.gastro.2022.07.086","article-title":"AGA clinical practice update on management of refractory celiac disease: expert review","volume":"163","author":"Green","year":"2022","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bpg.2025.102081_bib84","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/MCG.0b013e31827b507d","article-title":"Probiotic therapy for celiac disease","volume":"47","author":"Tavakkoli","year":"2013","journal-title":"J Clin Gastroenterol"},{"issue":"9","key":"10.1016\/j.bpg.2025.102081_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/nu12092674","article-title":"Probiotics, prebiotics and other dietary supplements for gut microbiota modulation in celiac disease patients","volume":"12","author":"Marasco","year":"2020","journal-title":"Nutrients"},{"issue":"7","key":"10.1016\/j.bpg.2025.102081_bib86","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1053\/j.gastro.2014.02.031","article-title":"Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease","volume":"146","author":"L\u00e4hdeaho","year":"2014","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.bpg.2025.102081_bib87","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3748\/wjg.v30.i11.1545","article-title":"Effect of Aspergillus Niger prolyl endopeptidase in patients with celiac disease on a long-term gluten-free diet","volume":"30","author":"Stefanolo","year":"2024","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.bpg.2025.102081_bib88","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.clim.2009.11.001","article-title":"The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo","volume":"134","author":"Tye-Din","year":"2010","journal-title":"Clin Immunol"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691825001088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691825001088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:09:30Z","timestamp":1773086970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691825001088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":85,"alternative-id":["S1521691825001088"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2025.102081","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistent symptoms and enteropathy in coeliac disease: clinical considerations and therapeutic opportunities","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2025.102081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102081"}}